Early Prostate Cancer Kept at Bay in Two Studies for High-Risk Men
- J&J, Pfizer drugs slow progression of most common tumor in men
- Could offer new treatments for cancer before it spreads
Source: beerkoff/iStockphoto/Getty Images
This article is for subscribers only.
Men with an early form of prostate cancer who are at high risk of seeing it spread and turn deadly may benefit from treatment with Johnson & Johnson and Pfizer Inc. drugs that slow progression of the disease.
J&J’s experimental medicine apalutamide and Pfizer’s prostate cancer drug Xtandi delayed the worsening of the most common tumor by more than 70 percent compared with a placebo in two separate studies. The results, which are being presented at a medical meeting devoted to genital and urinary cancers in San Francisco, could offer an alternative for men whose cancer is progressing yet considered early-stage because localized to their prostate.